NephroBlog: Pruritus and Hemodialysis
Patients with end-stage kidney disease on hemodialysis can have many different symptoms that affect their quality of life. While seeing patients in the dialysis unit, I often see many similar symptom complaints from patients. Complaints from patients on hemodialysis include post-dialysis fatigue (need to take a nap after dialysis, no energy to run errands, etc.), muscle cramps (at night, right after dialysis), and pruritus. Pruritus is the medical term for itchy skin that can affect the quality of life of a person. The pathophysiology of chronic kidney disease-associated pruritus (also known as hemodialysis-associated pruritus or uremic pruritus) is thought to be multifactorial: a combination of demographic, biologic, neuropathic, and psychogenic factors. One theory suggest interleukin-1 as a biological causes of pruritus. The pruritus is often worse at night and affects sleep quality in these patients.
Daraghmeh et al. published a cross-sectional study examining pruritus and sleep problems among hemodialysis patients in four different centers in Palestine. Using the 5-D itching score for pruritis and the Pittsburgh Sleep Quality Index (PSQI) score for sleep disturbances. Of the 250 participants, there were 121 with complaints of pruritus and 21% patients with severe symptoms. About 66% were classified as poor sleepers on the PSQI. Regression analysis showed that the 5-D itching score and the total number of comorbidities were significantly associated with the PSQI score, demonstrating that poor sleep quality is often due to pruritus.
A prior publication by Orasan et al. found that pruritus and poor sleep quality can significantly affect survival in this population. Survival differences were found in the 170 patients treated with hemodialysis or hemodiafiltration subdivided as having both pruritus/insomnia, pruritus alone, insomnia alone, or neither symptom. Survival at 20 months was lower in those patients with both pruritus and insomnia, highlighting that these symptoms are beyond a minor annoyance.
Takahashi et al. reported on development of a treatment algorithm using topical medications for pruritus that has shown effective results. The proportion of patients with pruritus decreased significantly from 96.6% in 2009 to 66.8% in 2018 with the use of this algorithm. The algorithm consisted of treatment with moisturizers alone; moisturizer and topical steroids; moisturizer, topical steroids and Nalfurafine; and moisturizer and Nalfurafine. Nalfurafine, which can be intravenous or orally administered, is a kappa opioid receptor agonist but unfortunately it is not available in the all countries. A newer agent, Difelikefalin, also a kappa opioid receptor agonist is showing promise. This medication is administered into the venous line of the dialysis circuit at each hemodialysis session.
Use of moisturizers applied several times a day is an important part of pruritus treatment. If there is no relief, adding a topical steroid or the addition of antihistamines, or agents to address neuropathy such as gabapentin or pregabalin are potential next steps. With the emergence of new medications like Difelikefalin this opens the door to some potentially better treatment algorithms.
The incessant itching does not just effect our patient’s quality of life but also their risk of survival. What is your treatment algorithm for chronic kidney disease-associated pruritus?
- Dr. Daphne Knicely
BMC Nephrology
Follow the Topic
-
BMC Nephrology
This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With collections, you can get published faster and increase your visibility.
Artificial intelligence in nephrology
BMC Nephrology welcomes submissions to a Collection on Artificial intelligence in nephrology.
Current research trends in nephrology represent the beginning of a new era of cross-disciplinary informational synthesis. With accelerating discoveries in genetics, molecular pathways, biochemical interactions and intercellular communication, new potential therapeutic targets are being introduced at an unprecedented rate. With application of novel methods in translational research and vast accumulation of clinical data, personalized treatment regimens have become central in advancing the quality of care and improving outcomes. Innovations in dialysis and transplant management, artificial kidney development, implementation of early diagnostic and disease prevention strategies are at the forefront of a modern patient-centered approach in nephrology.
The continuous flow of novel and constantly evolving information requires a powerful resource for high-level data synthesis and complex analysis in order to find meaning in a perpetually expanding informational field. Artificial Intelligence (AI) technologies, including Machine Learning (ML) are such resources, application of which in clinical and translational research is gaining momentum. The AI generated data-based knowledge has potential to impact patient management strategies by forming support systems for clinical decisions, improving drug design, risk identification and personalization of treatment. In all possible ways, AI and ML are enabling the emergence of “intelligent nephrology”.
This Collection gathers researchers with interest in kidney diseases from different perspectives, from basic science to clinical settings, including bioengineers and data scientists, aiming to present novel strategies of analysis to unravel the causes of renal diseases and improving in personalized therapeutics with the goal of achieving precision medicine. We encourage contributions with focus on the role of AI in novel data acquisition, synthesis, and interpretation, in scope with the journal’s aims in the diagnosis and treatment of renal diseases.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Apr 10, 2025
Pediatric chronic kidney disease: Transitioning into adult care
BMC Nephrology invites submissions to the collection exploring various aspects of this transition from childhood to adulthood including but not limited to:
Transitional care models: Exploring effective strategies
RISE to Transition program: Evaluating its impact
Pediatric to adult services integration: Challenges and solutions
Disease awareness among adolescents with CKD: Bridging gaps
Health-related quality of life in transitioning patients: Assessments and interventions
Enhancing self-management skills in young adults with CKD
Optimizing adult CKD services for transitional patients
Pediatric nephrology: Setting the stage for successful transitions
Multidisciplinary approaches to CKD transitional care
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: May 12, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in